PDF
Kurs & Likviditet
Beskrivning
| Land | Norge |
|---|---|
| Lista | OB Match |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Oslo, Norway, 3 November 2022 - Targovax ASA (OSE: TRVX), a clinical stage biotechnology company developing immune activators to target hard-to-treat solid tumors, today announces its third quarter 2022 results.
Members of Targovax's executive management team will give an online presentation to investors, analysts and the press at 10:00 CET today (details below).
THIRD QUARTER 2022 HIGHLIGHTS
ONCOS-102- The study protocol for the planned multi-cohort phase 2 in melanoma was approved by the US FDA
- The phase 1b melanoma study results were selected for oral presentation at the prestigious Society for Immunotherapy in Cancer (SITC) annual meeting
- The phase 1b melanoma study results were published in the high-impact oncology journal "Clinical Cancer Research"
- Key technical proof-of-concept data were established for the circRNA program
- Preparations progressed for the TG01 mutant KRAS trials - one in Norway and one in the USA
Erik Digman Wiklund, CEO commented: "It is a very exciting time to lead Targovax. We are building a great pipeline and have established a robust development strategy for our clinical stage products. During the third quarter we made important progress on all three of our strategic pillars, and Targovax is in a strong position to build success for both the clinical and pre-clinical parts of our portfolio."
Key figures
Amounts in NOK 3Q 2022 3Q 2021 9M 2022 9M 2021 FY 2021
thousands
Total operating - - - - -
revenues
Total operating -20 282 -22 539 -80 069 -70 078 -95 601
expenses
Operating -20 282 -22 539 -80 069 -70 078 -95 601
profit/loss
Net financial items -460 -781 -296 -1 294 -2 422
Income tax 10 11 31 42 52
Net profit/loss -20 732 -23 309 -80 333 -71 330 -97 971
Basic and diluted -0.11 -0.27 -0.43 -0.82 -1.10
EPS (NOK/share)
Net change in cash -29 612 -17 127 -85 496 -68 257 59 360
Cash and cash 125 798 71 192 181 682 122 321 122 321
equivalents start of
period
Cash and cash 96 186 54 064 96 186 54 064 181 682
equivalents end of
period
The interim financial information has not been subject to audit
Presentation
We invite to a live webcast today at 10.00 CET. You can join the webcast here (https://channel.royalcast.com/hegnarmedia/#!/hegnarmedia/20221103_8). It will be possible to submit questions during the presentation.
Reporting material
221103 TRVX 3Q report.pdf (https://mb.cision.com/Public/17093/3660342/b691e5b95c6dfe8c.pdf)
221103 TRVX 3Q presentation.pdf (https://mb.cision.com/Public/17093/3660342/9767c15424e1c764.pdf)
The quarterly report and presentation are also available at the website www.targovax.com (https://www.targovax.com/en/financial-reports/).